The Global Health Body Sounds Alert Over Severe Scarcity of Weight-Loss Jabs

Fewer than a tenth of people that would benefit from GLP-1 drugs like Wegovy have access to them, caution the World Health Organization as it issues its first guidance on the drugs.

Given over a billion individuals worldwide now living with obesity, it is calling for increased and just availability to GLP-1 medication.

According to forecasts, more than two billion are projected to be living with obesity by 2030 unless action is taken.

"Our new guidelines recognises that excess weight is a chronic disease that can be managed with comprehensive and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and logistical bottlenecks are major obstacles to broad access to the injections that can assist patients in reducing significant weight, explains the agency.

Skinny Jab Supply Crisis

Even in the present most favorable case, the supply of these medications might only reach around 100 million people – fewer than 10% of eligible patients, according to the health organization.

The advice urges governments and firms to expand availability, via approaches such as patent sharing.

A patent on a key compound – the primary ingredient of a leading brand – is set to lapse in several nations in 2026.

How Weight-Loss Injections Function

The injections imitate a body's own hormone to delay gastric emptying, suppress the appetite and enhance feelings of fullness so users reduce food intake.

People typically begin shedding pounds within a few weeks of starting on the once-weekly jabs.

Evidence suggests users may put most of the weight back on a year later of halting the treatment, because their typical appetite return.

To be overweight or obese increases your risk for experiencing health problems, such as diabetes, cardiovascular issues, brain attack, and some cancers.

Obesity affects people in all nations and was associated with over three and a half million fatalities worldwide in 2024, according to the health agency.